

MEETING ABSTRACT

Open Access

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial

Douglas Eugenio Barbieri*, Ran Duan, Jorge Gross, Bruno Linetzky, Janaina Martins De Lana, Arturo Rojas, Georgina Sposetti, Oded Stempa, Angel Rodriguez

From 20th Brazilian Diabetes Society Congress
Porto Alegre, Brazil. 11-18 November 2015

Background/aim

This post-hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation (Argentina, Brazil, and Mexico) of participants with type 2 diabetes mellitus (T2D).

Materials and methods

This phase 4, randomized, open-label, parallel-arm trial included participants aged 18–75 yrs. with T2D who were taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone and had glycosylated hemoglobin (HbA1c) between $\geq 7.5\%$ and $\leq 10.5\%$ and fasting plasma glucose ≤ 6.7 mmol/L (121 mg/dL). Participants were randomized 1: 1 to receive twice-daily LM25 (before breakfast and dinner) or basal insulin glargine (at bedtime) and IGL (before the largest daily meal) in addition to their existing dose of metformin and/or pioglitazone for 24 weeks. The primary efficacy outcome was the change in HbA1c from baseline to Week 24.

Results

A total of 162 participants (80 LM25; 82 IGL) with a mean (standard deviation [SD]) age of 57.3 (9.0) yrs. and

body mass index of 31.3 (5.2) kg/m² were included. The mean (SD) change in HbA1c (%) from baseline was -1.5 (1.0) in the LM25 group and -1.0 (1.2) in the IGL group (Figure 1). At Week 24, 35.1% of participants in the LM25 group and 31.6% of participants in the IGL group




Figure 1 Observed HbA1c levels at Baseline, Week 12, and Week 24 in patients receiving insulin lispro low mixture (LM25; 75% insulin lispro protamine suspension and 25% insulin lispro solution 25%) twice daily or basal insulin glargine once daily and prandial insulin lispro once daily (IGL). Abbreviation: HbA1c=glycosylated hemoglobin.

* Correspondence: dbarbieri@lilly.com
Universidade Federal de São Paulo, São Paulo, Brazil

achieved the target HbA1c <7.0%. Fasting blood glucose and glycemic variability at Week 24 were similar between the 2 groups, as was the mean (SD) total daily insulin dose (LM25=61.0 [27.6] IU; IGL=60.6 [24.3] IU). The mean (SD) rate of total hypoglycemia per 30 days was numerically similar between the two groups (LM25=1.6 [2.2]; IGL=1.8 [2.6] [overall study period]). Mean (SD) weight gain from baseline to Week 24 was 2.4 (2.9) kg in the LM25 group and 1.0 (3.1) kg in the IGL group. Treatment-emergent adverse events were similar between the 2 groups.

Conclusions

The results of this post-hoc analysis in a Latin American population are consistent with the results reported in the trial-level population and suggest that both LM25 and IGL are viable treatment options for insulin intensification in patients with T2D who do not achieve glyce-mic control on basal insulin glargine. ClinicalTrials.gov Number: NCT01175824.

Published: 11 November 2015

doi:10.1186/1758-5996-7-S1-A57

Cite this article as: Barbieri *et al.*: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial. *Diabetology & Metabolic Syndrome* 2015 **7**(Suppl 1):A57.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

